Biosimilar User Fee Collections Drop Well Below Estimates, But US FDA Not Worried

 
• By Derrick Gingery
  
FDA entrance sign 2016
Estimates for PDUFA and GDUFA were much closer to actual cash collections.
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Biosimilars & Generics